Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 6Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 15Carcinoma, Hepatocellular 13Urinary Bladder Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 9Neoplasms 8Carcinoma, Transitional Cell 8Stomach Neoplasms 7Neoplasm Metastasis 7Breast Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Carcinoma, Neuroendocrine 3Urethral Neoplasms 2Ureteral Neoplasms 2Turcot syndrome 2Solid Tumors 2Rectal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Glioma 2

Interventions

pembrolizumab 3olaparib 2atezolizumab 2Trastuzumab 2zimberelimab 1tocilizumab 1spartalizumab 1pralsetinib 1pertuzumab 1ipatasertib 1inavolisib 1fludarabine 1entrectinib 1alectinib 1Radiotherapy 1Methotrexate 1Immune Checkpoint Inhibitors 1Docetaxel 1Cyclophosphamide 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Solid Tumors × atezolizumab × Clear all
NCT04250155 2026-05-26

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Active not recruiting
195 enrolled
Other solid neoplasm

Solid Tumors

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡